Frank Condella
Follow
Get notifications in MyBN when activity occurs.
Frank Condella
Non-Executive Director, Chair since 2021 / Mayne Pharma Group
Frank Condella has over 30 years of experience in executive roles within the pharmaceutical industry.
His operating experience includes being chief executive of Juniper Pharmaceuticals, a US public-listed CDMO and specialty pharmaceutical company which was sold to Catalent. He was also chief executive of Skyepharma, president of European operations at IVAX (Teva), chief executive of Faulding Pharmaceuticals, vice president of Specialty Care Products at Roche, and vice president & general manager of the Lederle Standard Products (Pfizer).
His operating experience includes being chief executive of Juniper Pharmaceuticals, a US public-listed CDMO and specialty pharmaceutical company which was sold to Catalent. He was also chief executive of Skyepharma, president of European operations at IVAX (Teva), chief executive of Faulding Pharmaceuticals, vice president of Specialty Care Products at Roche, and vice president & general manager of the Lederle Standard Products (Pfizer).
Lists and Charts
Total Shareholder Return as at 31/10/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 636th | Mayne Pharma Group | 17% | -16% |
1740 WA (and selected non WA) listed companies ranked by
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| th |  | Mayne Pharma Group | $390.1m |
1334 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Person Activity
| REMUNERATION UPDATE: Non-Executive Director, Chair since 2021, Mayne Pharma Group | 13 Nov 2020 |
| NEW ROLE: Non-Executive Director, Chair since 2021, Mayne Pharma Group | 03 Nov 2020 |
